Percutaneous Large Hole Vascular Closure
Conditions
Keywords
Vascular Closure, Vascular Closure Device, Large hole percutaneous closure, Large bore percutaneous closure
Brief summary
The objective is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures.
Detailed description
The objective of this pivotal study is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures, with sufficient rigor to provide robust scientific evidence for the demonstration of clinical safety and efficacy of the PerQseal closure system to support a pre-market approval submission.
Interventions
DEVICEPerQseal® Closure Device System
Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
Sponsors
Vivasure Medical Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 19 years, 2. Clinically indicated for a percutaneous arterial interventional catheter-based procedure, e.g., transcatheter aortic valve replacement/implantation (TAVR/TAVI) or endovascular abdominal aortic aneurysm repair (EVAR), or thoracic endovascular aortic aneurysm repair (TEVAR), or use of a circulatory assist device or extracorporeal oxygenation using a common femoral arteriotomy created by a 12 to 22 F sheath (arteriotomy up to 26 F), 3. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements, 4. Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study. Baseline
Exclusion criteria
1. Evidence of current systemic bacterial or cutaneous infection, including groin infection, 2. Known bleeding diathesis, definite or potential coagulopathy, platelet count \< 100,000/µl or subjects on long term anticoagulants with an INR \> 2 within 12 hours prior to index procedure, 3. Significant anaemia (haemoglobin \< 9 g/dL or haematocrit \< 27%), within 24 hours prior to index procedure, 4. Known type II heparin-induced thrombocytopenia, 5. Documented left ventricular ejection fraction \< 20%, 6. Ipsilateral or contralateral lower extremity amputation. 7. Claudication (Rutherford category 3 or greater), documented untreated iliac or common femoral artery diameter stenosis \> 50% or previous bypass surgery/stent placement in the common femoral artery of target leg, 8. Known existing nerve damage in the target leg, 9. Renal insufficiency (Glomerular Filtration Rate ≤ 30 ml/min or baseline serum creatinine \> 2.5 mg/dL) or on renal replacement therapy, 10. Known allergy to any of the materials used in the PerQseal device (refer to Instructions for Use), 11. Subject unsuitable for surgical repair of the target leg access site, 12. Subject has undergone a percutaneous procedure greater than 8 F sheath in the target leg, within the 90-days prior to index procedure, 13. Subject has undergone a percutaneous procedure of 8 F sheath or less using an absorbable intravascular closure device for haemostasis, in the target leg, within the 90-days prior to index procedure, 14. Subject has undergone a percutaneous procedure of 8 F sheath or less using a suture mediated closure device or manual/mechanical pressure for haemostasis in the target leg, within the 30-days prior to index procedure, 15. Evidence of marked tortuosity of the femoral or external iliac arteries in the target leg, based on pre-primary procedure CT angiography, 16. Evidence of arterial diameter stenosis \> 30% within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography, 17. Evidence of anterior wall calcification of the target common femoral artery (other than small, diffuse deposits which in the opinion of the investigator will not impede the vascular closure procedure) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography, 18. Target femoral artery diameter is less than 6 mm or 7 mm, depending on whether S (small) or L (large) PerQseal Introducer will be used for arteriotomy closure, respectively, based on pre-primary procedure CT angiography, 19. Further planned endovascular/catheter-based procedure in the target leg in the 30-days following the index procedure. 20. Subject is enrolled in another investigational medical device or drug study, 21. Subject has been previously enrolled in this clinical study. 22. Current COVID-19 infection (with or without symptoms), recent positive test for COVID-19 within two weeks, or recent exposure to a person with COVID-19 infection within two weeks. Procedural
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Safety Endpoint - Major Access Site Complications | through 30 days | Rate of major access site complications attributable to the PerQseal device |
| Primary Effectiveness Endpoint - Time to Hemostasis | 20 Minutes | Elapsed time in minutes from PerQseal (Introducer-sheath and Delivery Device) removal to first observed cessation of common femoral artery (CFA) bleeding, excluding cutaneous or subcutaneous oozing, and in the absence of a developing haematoma. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Safety Endpoint - Minor Access Site Complications | through 30 Days | Incidence of minor access site complications attributable to the PerQseal device |
| Secondary Effectiveness Endpoint - PerQseal Technical Success Rate | 10 Minutes | Defined as the number of PerQseal devices that are deployed and achieve haemostasis (i.e., cessation of arterial bleeding excluding cutaneous or subcutaneous oozing) without need for more than 10 minutes of firm, adjunctive manual compression or alternative treatment (other than adjunctive endovascular ballooning) at target access site, divided by the total number of PerQseal devices where deployment was attempted. This is a per device endpoint. |
| Secondary Effectiveness Endpoint - PerQseal Treatment Success Rate | through 30 days | Defined as the number of subjects who meet PerQseal Technical Success without experiencing a device related Major Access Site Complication through 30-days, divided by the total number of subjects where PerQseal device deployment was attempted. |
| Secondary Effectiveness Endpoint - Total Closure Time | 40 Minutes | Defined as time to Haemostasis plus Time to Device Deployment. |
| Secondary Effectiveness Endpoint - Time to Ambulation | through 24 hours | Defined as the elapsed time from PerQseal removal until the subject can walk 20 feet/ 6 meters without arterial re-bleeding at the target access site. This endpoint will be evaluated only for subjects who are ambulatory (e.g., not confined to wheelchair or bed) at time of enrolment. |
| Secondary Effectiveness Endpoint - Time to Device Deployment | 20 Minutes | Defined as the time from insertion of the PerQseal delivery device into the PerQseal Introducer sheath to complete removal of the PerQseal (delivery device and introducer-sheath) from the subject following PerQseal deployment. |
Countries
Germany, United States
Outcome results
None listed